ERBB2 and ovarian carcinoma: As part of the non-randomized, multicenter, phase II DESTINY-PanTumor02 study (NCT04482309), trastuzumab deruxtecan (T-DXd) was evaluated in 40 patients with platinum-resistant, HER2-expressing ovarian cancer (IHC 3+ or 2+), demonstrating encouraging results with an overall response rate (ORR) of 45% and a median duration of response (DOR) of 11.3 months [68].